People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Earlier phases of the trial showed promising results, with a single 25mg dose of COMP360 psilocybin, combined with psychological support, significantly reducing depressive symptoms after three weeks, ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel mechanisms of action.

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...